Market revenue in 2022 | USD 606.3 million |
Market revenue in 2030 | USD 1,124.7 million |
Growth rate | 8% (CAGR from 2022 to 2030) |
Largest segment | Estrogen and progesterone replacement therapy |
Fastest growing segment | Parathyroid Hormone replacement |
Historical data | 2018 - 2021 |
Base year | 2022 |
Forecast period | 2023 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Estrogen and Progesterone Replacement Therapy, HGH replacement therapy, Thryoid hormone replacement therapy, Testosterone Replacement Therapy, Parathyroid Hormone replacement |
Key market players worldwide | Eli Lilly and Co, Bayer AG, Hisamitsu Pharmaceutical Co Inc, Pfizer Inc, Merck & Co Inc, Viatris Inc, Novo Nordisk A/S ADR, AbbVie Inc, Roche Holding AG ADR, Ascend Wellness Holdings Inc |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to hormone replacement therapy market will help companies and investors design strategic landscapes.
Estrogen and progesterone replacement therapy was the largest segment with a revenue share of 53.41% in 2022. Horizon Databook has segmented the India hormone replacement therapy market based on estrogen and progesterone replacement therapy, hgh replacement therapy, thryoid hormone replacement therapy, testosterone replacement therapy, parathyroid hormone replacement covering the revenue growth of each sub-segment from 2018 to 2030.
The hormonal replacement therapy market in India is expected to grow over the forecast period. The market growth can be attributed to the local presence of big pharmaceutical firms, such as Lupin, Abbott, Merck & Co., Inc., F. Hoffmann-La Roche Ltd., and Eli Lilly and Company, and their strong hormone replacement therapy product portfolios for the treatment of various diseases.
Currently, in India, the cost of testosterone replacement is around USD 40 to USD 100 monthly for patients The increasing prevalence of hypothyroidism is projected to fuel market growth. As per the Hindu News, in May 2021, around 42 million people in India suffered from different thyroid-associated diseases.
Hypothyroidism is three times more common among women and one in every 10 adults is living with this disease. In addition, secondary diseases such as diabetes contribute to the rising prevalence of hypothyroidism, as one in every three diabetic patients could have an underlying thyroid disorder.
Horizon Databook provides a detailed overview of country-level data and insights on the India hormone replacement therapy market , including forecasts for subscribers. This country databook contains high-level insights into India hormone replacement therapy market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account